Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 314 entries
Sorted by: Best Match Show Resources per page
Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction.

Heart failure reviews

Dal Canto E, Remmelzwaal S, van Ballegooijen AJ, Handoko ML, Heymans S, van Empel V, Paulus WJ, Nijpels G, Elders P, Beulens JW.
PMID: 32488580
Heart Fail Rev. 2022 Jan;27(1):207-218. doi: 10.1007/s10741-020-09985-1.

This study aimed to evaluate the diagnostic performance of echocardiographic markers of heart failure with preserved ejection fraction (HFpEF) and left ventricular diastolic dysfunction (LVDD) in comparison with the gold standard of cardiac catheterization. Diagnosing HFpEF is challenging, as...

Cite
Dal Canto E, Remmelzwaal S, van Ballegooijen AJ, et al. Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction. Heart Fail Rev. 2022;27(1):207-218doi: 10.1007/s10741-020-09985-1.
Dal Canto, E., Remmelzwaal, S., van Ballegooijen, A. J., Handoko, M. L., Heymans, S., van Empel, V., Paulus, W. J., Nijpels, G., Elders, P., & Beulens, J. W. (2022). Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction. Heart failure reviews, 27(1), 207-218. https://doi.org/10.1007/s10741-020-09985-1
Dal Canto, Elisa, et al. "Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction." Heart failure reviews vol. 27,1 (2022): 207-218. doi: https://doi.org/10.1007/s10741-020-09985-1
Dal Canto E, Remmelzwaal S, van Ballegooijen AJ, Handoko ML, Heymans S, van Empel V, Paulus WJ, Nijpels G, Elders P, Beulens JW. Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction. Heart Fail Rev. 2022 Jan;27(1):207-218. doi: 10.1007/s10741-020-09985-1. PMID: 32488580.
Copy Download .nbib Format: NLM
Hormonal prostate cancer therapies and cardiovascular disease: a systematic review.

Heart failure reviews

Cereda V, Falbo PT, Manna G, Iannace A, Menghi A, Corona M, Semenova D, Calò L, Carnevale R, Frati G, Lanzetta G.
PMID: 32500365
Heart Fail Rev. 2022 Jan;27(1):119-134. doi: 10.1007/s10741-020-09984-2.

Therapeutic intervention for prostate cancer mostly relies on eliminating circulating androgen or antagonizing its effect at the cellular level. As the use of endocrine therapies grows, an under-reported incidence of cardiovascular toxicities occurs in prostate cancer patients. In this...

Cite
Cereda V, Falbo PT, Manna G, et al. Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. Heart Fail Rev. 2022;27(1):119-134doi: 10.1007/s10741-020-09984-2.
Cereda, V., Falbo, P. T., Manna, G., Iannace, A., Menghi, A., Corona, M., Semenova, D., Calò, L., Carnevale, R., Frati, G., & Lanzetta, G. (2022). Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. Heart failure reviews, 27(1), 119-134. https://doi.org/10.1007/s10741-020-09984-2
Cereda, Vittore, et al. "Hormonal prostate cancer therapies and cardiovascular disease: a systematic review." Heart failure reviews vol. 27,1 (2022): 119-134. doi: https://doi.org/10.1007/s10741-020-09984-2
Cereda V, Falbo PT, Manna G, Iannace A, Menghi A, Corona M, Semenova D, Calò L, Carnevale R, Frati G, Lanzetta G. Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. Heart Fail Rev. 2022 Jan;27(1):119-134. doi: 10.1007/s10741-020-09984-2. PMID: 32500365.
Copy Download .nbib Format: NLM
Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?.

Heart failure reviews

Vecchi AL, Abete R, Marazzato J, Iacovoni A, Mortara A, De Ponti R, Senni M.
PMID: 32556671
Heart Fail Rev. 2022 Jan;27(1):103-110. doi: 10.1007/s10741-020-09991-3.

The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ejection fraction (HFrEF) has more than halved the risk of sudden cardiac death (SCD) in this setting. However, SCD remains one of the major...

Cite
Vecchi AL, Abete R, Marazzato J, et al. Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. Heart Fail Rev. 2022;27(1):103-110doi: 10.1007/s10741-020-09991-3.
Vecchi, A. L., Abete, R., Marazzato, J., Iacovoni, A., Mortara, A., De Ponti, R., & Senni, M. (2022). Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. Heart failure reviews, 27(1), 103-110. https://doi.org/10.1007/s10741-020-09991-3
Vecchi, Andrea Lorenzo, et al. "Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?." Heart failure reviews vol. 27,1 (2022): 103-110. doi: https://doi.org/10.1007/s10741-020-09991-3
Vecchi AL, Abete R, Marazzato J, Iacovoni A, Mortara A, De Ponti R, Senni M. Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. Heart Fail Rev. 2022 Jan;27(1):103-110. doi: 10.1007/s10741-020-09991-3. PMID: 32556671.
Copy Download .nbib Format: NLM
Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2.

Heart failure reviews

Gupta S, Mitra A.
PMID: 33426593
Heart Fail Rev. 2022 Jan;27(1):239-249. doi: 10.1007/s10741-021-10076-y. Epub 2021 Jan 11.

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), a highly pathogenic member of family coronaviridae, has caused an exponentially growing global pandemic termed as the coronavirus disease 2019 (COVID-19) with more than 12 million cases worldwide till date. This deadly disease...

Cite
Gupta S, Mitra A. Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. Heart Fail Rev. 2021;27(1):239-249doi: 10.1007/s10741-021-10076-y.
Gupta, S., & Mitra, A. (2022). Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. Heart failure reviews, 27(1), 239-249. https://doi.org/10.1007/s10741-021-10076-y
Gupta, Shreyasi, and Mitra, Arkadeep. "Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2." Heart failure reviews vol. 27,1 (2022): 239-249. doi: https://doi.org/10.1007/s10741-021-10076-y
Gupta S, Mitra A. Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. Heart Fail Rev. 2022 Jan;27(1):239-249. doi: 10.1007/s10741-021-10076-y. Epub 2021 Jan 11. PMID: 33426593; PMCID: PMC7797272.
Copy Download .nbib Format: NLM
Immunity and inflammation: the neglected key players in congenital heart disease?.

Heart failure reviews

Wienecke LM, Cohen S, Bauersachs J, Mebazaa A, Chousterman BG.
PMID: 34855062
Heart Fail Rev. 2021 Dec 02; doi: 10.1007/s10741-021-10187-6. Epub 2021 Dec 02.

Although more than 90% of children born with congenital heart disease (CHD) survive into adulthood, patients face significantly higher and premature morbidity and mortality. Heart failure as well as non-cardiac comorbidities represent a striking and life-limiting problem with need...

Cite
Wienecke LM, Cohen S, Bauersachs J, et al. Immunity and inflammation: the neglected key players in congenital heart disease?. Heart Fail Rev. 2021;doi: 10.1007/s10741-021-10187-6.
Wienecke, L. M., Cohen, S., Bauersachs, J., Mebazaa, A., & Chousterman, B. G. (2021). Immunity and inflammation: the neglected key players in congenital heart disease?. Heart failure reviews, . https://doi.org/10.1007/s10741-021-10187-6
Wienecke, Laura M, et al. "Immunity and inflammation: the neglected key players in congenital heart disease?." Heart failure reviews vol. (2021). doi: https://doi.org/10.1007/s10741-021-10187-6
Wienecke LM, Cohen S, Bauersachs J, Mebazaa A, Chousterman BG. Immunity and inflammation: the neglected key players in congenital heart disease?. Heart Fail Rev. 2021 Dec 02; doi: 10.1007/s10741-021-10187-6. Epub 2021 Dec 02. PMID: 34855062; PMCID: PMC8636791.
Copy Download .nbib Format: NLM
Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.

Heart failure reviews

Orphanou N, Papatheodorou E, Anastasakis A.
PMID: 34263412
Heart Fail Rev. 2021 Jul 14; doi: 10.1007/s10741-021-10139-0. Epub 2021 Jul 14.

Dilated cardiomyopathy (DCM) is an umbrella term entailing a wide variety of genetic and non-genetic etiologies, leading to left ventricular systolic dysfunction and dilatation, not explained by abnormal loading conditions or coronary artery disease. The clinical presentation can vary...

Cite
Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev. 2021;doi: 10.1007/s10741-021-10139-0.
Orphanou, N., Papatheodorou, E., & Anastasakis, A. (2021). Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart failure reviews, . https://doi.org/10.1007/s10741-021-10139-0
Orphanou, Nicoletta, et al. "Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments." Heart failure reviews vol. (2021). doi: https://doi.org/10.1007/s10741-021-10139-0
Orphanou N, Papatheodorou E, Anastasakis A. Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments. Heart Fail Rev. 2021 Jul 14; doi: 10.1007/s10741-021-10139-0. Epub 2021 Jul 14. PMID: 34263412; PMCID: PMC8279384.
Copy Download .nbib Format: NLM
Challenges and the innovations in the care of advanced heart failure patients during COVID-19.

Heart failure reviews

Yehya A, Shah KS, Mitter SS, Ibrahim NE, Sperry B, Shah M, Chaudhry SP, Rajagopalan N, Hernandez-Montfort J, Mohan R, Alexander KM, Sinha S, Butler J, Kittleson MM.
PMID: 33432419
Heart Fail Rev. 2022 Jan;27(1):235-238. doi: 10.1007/s10741-021-10074-0. Epub 2021 Jan 12.

The COVID-19 pandemic underscored our healthcare system's unpreparedness to manage an unprecedented pandemic. Heart failure (HF) physicians from 14 different academic and private practice centers share their systems' challenges and innovations to care for patients with HF, heart transplantation,...

Cite
Yehya A, Shah KS, Mitter SS, et al. Challenges and the innovations in the care of advanced heart failure patients during COVID-19. Heart Fail Rev. 2021;27(1):235-238doi: 10.1007/s10741-021-10074-0.
Yehya, A., Shah, K. S., Mitter, S. S., Ibrahim, N. E., Sperry, B., Shah, M., Chaudhry, S. P., Rajagopalan, N., Hernandez-Montfort, J., Mohan, R., Alexander, K. M., Sinha, S., Butler, J., & Kittleson, M. M. (2022). Challenges and the innovations in the care of advanced heart failure patients during COVID-19. Heart failure reviews, 27(1), 235-238. https://doi.org/10.1007/s10741-021-10074-0
Yehya, Amin, et al. "Challenges and the innovations in the care of advanced heart failure patients during COVID-19." Heart failure reviews vol. 27,1 (2022): 235-238. doi: https://doi.org/10.1007/s10741-021-10074-0
Yehya A, Shah KS, Mitter SS, Ibrahim NE, Sperry B, Shah M, Chaudhry SP, Rajagopalan N, Hernandez-Montfort J, Mohan R, Alexander KM, Sinha S, Butler J, Kittleson MM. Challenges and the innovations in the care of advanced heart failure patients during COVID-19. Heart Fail Rev. 2022 Jan;27(1):235-238. doi: 10.1007/s10741-021-10074-0. Epub 2021 Jan 12. PMID: 33432419; PMCID: PMC7801155.
Copy Download .nbib Format: NLM
Current and emerging drug targets in heart failure treatment.

Heart failure reviews

Ghionzoli N, Gentile F, Del Franco AM, Castiglione V, Aimo A, Giannoni A, Burchielli S, Cameli M, Emdin M, Vergaro G.
PMID: 34273070
Heart Fail Rev. 2021 Jul 17; doi: 10.1007/s10741-021-10137-2. Epub 2021 Jul 17.

After initial strategies targeting inotropism and congestion, the neurohormonal interpretative model of heart failure (HF) pathophysiology has set the basis for current pharmacological management of HF, as most of guideline recommended drug classes, including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin...

Cite
Ghionzoli N, Gentile F, Del Franco AM, et al. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2021;doi: 10.1007/s10741-021-10137-2.
Ghionzoli, N., Gentile, F., Del Franco, A. M., Castiglione, V., Aimo, A., Giannoni, A., Burchielli, S., Cameli, M., Emdin, M., & Vergaro, G. (2021). Current and emerging drug targets in heart failure treatment. Heart failure reviews, . https://doi.org/10.1007/s10741-021-10137-2
Ghionzoli, Nicolò, et al. "Current and emerging drug targets in heart failure treatment." Heart failure reviews vol. (2021). doi: https://doi.org/10.1007/s10741-021-10137-2
Ghionzoli N, Gentile F, Del Franco AM, Castiglione V, Aimo A, Giannoni A, Burchielli S, Cameli M, Emdin M, Vergaro G. Current and emerging drug targets in heart failure treatment. Heart Fail Rev. 2021 Jul 17; doi: 10.1007/s10741-021-10137-2. Epub 2021 Jul 17. PMID: 34273070.
Copy Download .nbib Format: NLM
The use of diflunisal for transthyretin cardiac amyloidosis: a review.

Heart failure reviews

Ibrahim M, Saint Croix GR, Lacy S, Fattouh M, Barillas-Lara MI, Behrooz L, Mechanic O.
PMID: 34272629
Heart Fail Rev. 2021 Jul 16; doi: 10.1007/s10741-021-10143-4. Epub 2021 Jul 16.

Transthyretin cardiac amyloidosis (ATTR-CM) is caused by the accumulation of misfolded transthyretin (TTR) protein in the myocardium. Diflunisal, an agent that stabilizes TTR, has been used as an off-label therapeutic for ATTR-CM. Given limited data surrounding the use of...

Cite
Ibrahim M, Saint Croix GR, Lacy S, et al. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev. 2021;doi: 10.1007/s10741-021-10143-4.
Ibrahim, M., Saint Croix, G. R., Lacy, S., Fattouh, M., Barillas-Lara, M. I., Behrooz, L., & Mechanic, O. (2021). The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart failure reviews, . https://doi.org/10.1007/s10741-021-10143-4
Ibrahim, Michel, et al. "The use of diflunisal for transthyretin cardiac amyloidosis: a review." Heart failure reviews vol. (2021). doi: https://doi.org/10.1007/s10741-021-10143-4
Ibrahim M, Saint Croix GR, Lacy S, Fattouh M, Barillas-Lara MI, Behrooz L, Mechanic O. The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev. 2021 Jul 16; doi: 10.1007/s10741-021-10143-4. Epub 2021 Jul 16. PMID: 34272629.
Copy Download .nbib Format: NLM
Cardiac .

Heart failure reviews

Gupta A, Houston B.
PMID: 33409666
Heart Fail Rev. 2021 Jul;26(4):839-859. doi: 10.1007/s10741-020-10059-5. Epub 2021 Jan 07.

Continued advances in laboratory medicine are required to realize the potential of individualized medicine to impact common cardiovascular diseases. Magnetic resonance imaging (MRI) and spectroscopy (MRS) techniques have advanced over recent years and offer unique, powerful insights into cardiac...

Cite
Gupta A, Houston B. Cardiac . Heart Fail Rev. 2021;26(4):839-859doi: 10.1007/s10741-020-10059-5.
Gupta, A., & Houston, B. (2021). Cardiac . Heart failure reviews, 26(4), 839-859. https://doi.org/10.1007/s10741-020-10059-5
Gupta, Ashish, and Houston, Brian. "Cardiac ." Heart failure reviews vol. 26,4 (2021): 839-859. doi: https://doi.org/10.1007/s10741-020-10059-5
Gupta A, Houston B. Cardiac . Heart Fail Rev. 2021 Jul;26(4):839-859. doi: 10.1007/s10741-020-10059-5. Epub 2021 Jan 07. PMID: 33409666.
Copy Download .nbib Format: NLM
Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress.

Heart failure reviews

Li A, Zheng N, Ding X.
PMID: 33950478
Heart Fail Rev. 2021 May 05; doi: 10.1007/s10741-021-10109-6. Epub 2021 May 05.

Metabolic syndrome (MetS) refers to a group of cardiovascular risk elements comprising insulin resistance, obesity, dyslipidemia, increased glucose intolerance, and increased blood pressure. Individually, all the MetS components can lead to cardiac dysfunction, while their combination generates additional risks...

Cite
Li A, Zheng N, Ding X. Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart Fail Rev. 2021;doi: 10.1007/s10741-021-10109-6.
Li, A., Zheng, N., & Ding, X. (2021). Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart failure reviews, . https://doi.org/10.1007/s10741-021-10109-6
Li, Aoxue, et al. "Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress." Heart failure reviews vol. (2021). doi: https://doi.org/10.1007/s10741-021-10109-6
Li A, Zheng N, Ding X. Mitochondrial abnormalities: a hub in metabolic syndrome-related cardiac dysfunction caused by oxidative stress. Heart Fail Rev. 2021 May 05; doi: 10.1007/s10741-021-10109-6. Epub 2021 May 05. PMID: 33950478.
Copy Download .nbib Format: NLM
Weighing in on heart failure: the potential impact of bariatric surgery.

Heart failure reviews

Datta T, Lee AJ, Cain R, McCarey M, Whellan DJ.
PMID: 33495937
Heart Fail Rev. 2021 Jan 25; doi: 10.1007/s10741-021-10078-w. Epub 2021 Jan 25.

Obesity is a growing worldwide epidemic with significant economic burden that carries with it impacts on every physiologic system including the cardiovascular system. Specifically, the risk of heart failure has been shown to increase dramatically in obese individuals. The...

Cite
Datta T, Lee AJ, Cain R, et al. Weighing in on heart failure: the potential impact of bariatric surgery. Heart Fail Rev. 2021;doi: 10.1007/s10741-021-10078-w.
Datta, T., Lee, A. J., Cain, R., McCarey, M., & Whellan, D. J. (2021). Weighing in on heart failure: the potential impact of bariatric surgery. Heart failure reviews, . https://doi.org/10.1007/s10741-021-10078-w
Datta, Tanuka, et al. "Weighing in on heart failure: the potential impact of bariatric surgery." Heart failure reviews vol. (2021). doi: https://doi.org/10.1007/s10741-021-10078-w
Datta T, Lee AJ, Cain R, McCarey M, Whellan DJ. Weighing in on heart failure: the potential impact of bariatric surgery. Heart Fail Rev. 2021 Jan 25; doi: 10.1007/s10741-021-10078-w. Epub 2021 Jan 25. PMID: 33495937.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 314 entries